The new data gives BMS an opportunity to extend its lead over Cytokinetics, in pursuit of mavacamten with its rival cardiac myosin inhibitor ... has previewed an AI model that it believes will ...

And in December 2022 an FDA advisory committee voted against approval of Cytokinetics' cardiac myosin inhibitor omecamtiv mecarbil for heart failure, saying the data for the drug was not strong ...

Get the full experience! Unlock access to all videos with the Unlimited Trains.com Membership.